組蛋白修飾與胃腸道惡性腫瘤的關系_《中國普外基礎與臨床雜志》

作者：

孟春風 , 戴冬秋

中國醫科大學附屬第一醫院腫瘤外科（沈陽110001）;

關鍵詞：

胃腸道惡性腫瘤基因組蛋白修飾

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的　探討組蛋白修飾與胃腸道惡性腫瘤的關系。
方法　復習組蛋白修飾以及組蛋白修飾與胃腸道惡性腫瘤之間關系的相關文獻并進行綜述。
結果　組蛋白的修飾為表遺傳改變之一，能導致基因表達的改變，在惡性腫瘤的發生、發展中起重要作用。DNA甲基化與組蛋白修飾間相互作用，形成復雜系統，維持基因沉默。表觀遺傳修飾具有可逆性，逆轉表觀遺傳修飾，從而改變基因表達狀態，可能使惡性腫瘤細胞正常化（稱為表觀基因治療）。表觀基因治療對于胃腸道惡性腫瘤的預防和治療具有廣闊的應用前景，但還有許多問題需進一步研究證實。
結論　組蛋白修飾與胃腸道惡性腫瘤的發生有關，逆轉表觀遺傳修飾導致的基因表達改變對于胃腸道惡性腫瘤的預防和治療具有重要意義。

引用本文： 孟春風,戴冬秋. 組蛋白修飾與胃腸道惡性腫瘤的關系. 中國普外基礎與臨床雜志, 2007, 14(5): 608-611. doi: 復制

1.	Wolffe AP, Matzke MA. Epigenetics: regulation through repression [J]. Science， 1999; 286(5439)∶481.
2.	Feinberg AP, Vogelstein B. Hypomethylation distinguishes ge-nes of some human cancers from their normal counterparts [J]. Nature， 1983; 301(5895)∶89.
3.	Strahl BD, Allis CD. The language of covalent histone modifications [J]. Nature， 2000; 403(6765)∶41.
4.	楊少輝，戴冬秋. 腫瘤抑制基因甲基化與胃癌 [J]. 中國普外基礎與臨床雜志， 2006； 13（5）∶614.
5.	Rea S, Eisenhaber F, O’Carroll D, et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases [J]. Nature， 2000; 406(6796)∶593.
6.	Jenuwein T, Allis CD. Translating the histone code [J]. Science， 2001; 293(5532)∶1074.
7.	Wang H, Cao R, Xia L, et al. Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase [J]. Mol Cell， 2001; 8(6)∶1207.
8.	Schubeler D, MacAlpine DM, Scalzo D, et al. The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote [J]. Genes Dev， 2004; 18(11)∶1263.
9.	Liang G, Lin JC, Wei V, et al. Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome [J]. Proc Natl Acad Sci USA， 2004; 101(19)∶7357.
10.	Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1 [J]. Cell， 2004; 119(7)∶941.
11.	Mahadevan LC, Willis AC, Barratt MJ. Rapid histone H3 ph-osphorylation in response to growth factors, phorbol esters, okadaic acid, and protein synthesis inhibitors [J]. Cell， 1991; 65(5)∶775.
12.	Nowak SJ, Corces VG. Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation [J]. Trends Genet， 2004; 20(4)∶214.
13.	Salvador LM, Park Y, Cottom J, et al. Follicle-stimulating hormone stimulates protein kinase A-mediated histone H3 phosphorylation and acetylation leading to select gene activation in ovarian granulosa cells [J]. J Biol Chem， 2001; 276(43)∶40146.
14.	Cheung P, Allis CD, Sassone-Corsi P. Signaling to chromatin through histone modifications [J]. Cell， 2000; 103(2)∶263.
15.	Nowak SJ, Corces VG. Phosphorylation of histone H3 correlates with transcriptionally active loci [J]. Genes Dev， 2000; 14(23)∶3003.
16.	Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer [J]. Nat Genet， 1999; 21(1)∶103.
17.	Kondo Y, Shen L, Issa JP. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer [J]. Mol Cell Biol， 2003; 23(1)∶206.
18.	Fahrner JA, Eguchi S, Herman JG, et al. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer [J]. Cancer Res， 2002; 62(24)∶7213.
19.	Fuks F， Hurd PJ， Wolf D， et al. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation [J]. J Biol Chem， 2003; 278(6)∶4035.
20.	Bachman KE, Park BH, Rhee I, et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene [J]. Cancer Cell， 2003; 3(1)∶89.
21.	Cheung P, Tanner KG, Cheung WL, et al. Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation [J]. Mol Cell， 2000; 5(6)∶905.
22.	Lo WS, Trievel RC, Rojas JR, et al. Phosphorylation of serine 10 in histone H3 is functionally linked in vitro and in vivo to Gcn5-mediated acetylation at lysine 14 [J]. Mol Cell， 2000; 5(6)∶917.
23.	Zhang Y, Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails [J]. Genes Dev， 2001; 15(18)∶2343.
24.	Wang H, Huang ZQ, Xia L, et al. Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor [J]. Science， 2001; 293(5531)∶853.
25.	Fang JY, Chen YX, Lu J, et al. Epigenetic modification regulates both expression of tumor-associated genes and cell cycle progressing in human colon cancer cell lines: Colo-320 and SW1116 [J]. Cell Res， 2004; 14(3)∶217.
26.	Mitani Y, Oue N, Hamai Y, et al. Histone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma [J]. J Pathol， 2005; 205(1)∶65.
27.	Hamai Y, Oue N, Mitani Y, et al. DNA hypermethylation and histone hypoacetylation of the HLTF gene are associated with reduced expression in gastric carcinoma [J]. Cancer Sci， 2003; 94(8)∶692.
28.	Loprevite M, Tiseo M, Grossi F, et al. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines [J]. Oncol Res， 2005; 15(1)∶39.
29.	Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy [J]. Nature， 2004; 429(6990)∶457.
30.	Dobosy JR, Roberts JL, Fu VX, et al. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia [J]. J Urol， 2007; 177(3)∶822.
31.	Kaminskas E, Farrell A, Abraham S, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes [J]. Clin Cancer Res, 2005; 11(10)∶3604.

1. 　Wolffe AP, Matzke MA. Epigenetics: regulation through repression [J]. Science， 1999; 286(5439)∶481.
2. 　Feinberg AP, Vogelstein B. Hypomethylation distinguishes ge-nes of some human cancers from their normal counterparts [J]. Nature， 1983; 301(5895)∶89.
3. 　Strahl BD, Allis CD. The language of covalent histone modifications [J]. Nature， 2000; 403(6765)∶41.
4. 　楊少輝，戴冬秋. 腫瘤抑制基因甲基化與胃癌 [J]. 中國普外基礎與臨床雜志， 2006； 13（5）∶614.
5. 　Rea S, Eisenhaber F, O’Carroll D, et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases [J]. Nature， 2000; 406(6796)∶593.
6. 　Jenuwein T, Allis CD. Translating the histone code [J]. Science， 2001; 293(5532)∶1074.
7. 　Wang H, Cao R, Xia L, et al. Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase [J]. Mol Cell， 2001; 8(6)∶1207.
8. 　Schubeler D, MacAlpine DM, Scalzo D, et al. The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote [J]. Genes Dev， 2004; 18(11)∶1263.
9. 　Liang G, Lin JC, Wei V, et al. Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome [J]. Proc Natl Acad Sci USA， 2004; 101(19)∶7357.
10. 　Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1 [J]. Cell， 2004; 119(7)∶941.
11. 　Mahadevan LC, Willis AC, Barratt MJ. Rapid histone H3 ph-osphorylation in response to growth factors, phorbol esters, okadaic acid, and protein synthesis inhibitors [J]. Cell， 1991; 65(5)∶775.
12. 　Nowak SJ, Corces VG. Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation [J]. Trends Genet， 2004; 20(4)∶214.
13. 　Salvador LM, Park Y, Cottom J, et al. Follicle-stimulating hormone stimulates protein kinase A-mediated histone H3 phosphorylation and acetylation leading to select gene activation in ovarian granulosa cells [J]. J Biol Chem， 2001; 276(43)∶40146.
14. 　Cheung P, Allis CD, Sassone-Corsi P. Signaling to chromatin through histone modifications [J]. Cell， 2000; 103(2)∶263.
15. 　Nowak SJ, Corces VG. Phosphorylation of histone H3 correlates with transcriptionally active loci [J]. Genes Dev， 2000; 14(23)∶3003.
16. 　Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer [J]. Nat Genet， 1999; 21(1)∶103.
17. 　Kondo Y, Shen L, Issa JP. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer [J]. Mol Cell Biol， 2003; 23(1)∶206.
18. 　Fahrner JA, Eguchi S, Herman JG, et al. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer [J]. Cancer Res， 2002; 62(24)∶7213.
19. 　Fuks F， Hurd PJ， Wolf D， et al. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation [J]. J Biol Chem， 2003; 278(6)∶4035.
20. 　Bachman KE, Park BH, Rhee I, et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene [J]. Cancer Cell， 2003; 3(1)∶89.
21. 　Cheung P, Tanner KG, Cheung WL, et al. Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation [J]. Mol Cell， 2000; 5(6)∶905.
22. 　Lo WS, Trievel RC, Rojas JR, et al. Phosphorylation of serine 10 in histone H3 is functionally linked in vitro and in vivo to Gcn5-mediated acetylation at lysine 14 [J]. Mol Cell， 2000; 5(6)∶917.
23. 　Zhang Y, Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails [J]. Genes Dev， 2001; 15(18)∶2343.
24. 　Wang H, Huang ZQ, Xia L, et al. Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor [J]. Science， 2001; 293(5531)∶853.
25. 　Fang JY, Chen YX, Lu J, et al. Epigenetic modification regulates both expression of tumor-associated genes and cell cycle progressing in human colon cancer cell lines: Colo-320 and SW1116 [J]. Cell Res， 2004; 14(3)∶217.
26. 　Mitani Y, Oue N, Hamai Y, et al. Histone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma [J]. J Pathol， 2005; 205(1)∶65.
27. 　Hamai Y, Oue N, Mitani Y, et al. DNA hypermethylation and histone hypoacetylation of the HLTF gene are associated with reduced expression in gastric carcinoma [J]. Cancer Sci， 2003; 94(8)∶692.
28. 　Loprevite M, Tiseo M, Grossi F, et al. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines [J]. Oncol Res， 2005; 15(1)∶39.
29. 　Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy [J]. Nature， 2004; 429(6990)∶457.
30. 　Dobosy JR, Roberts JL, Fu VX, et al. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia [J]. J Urol， 2007; 177(3)∶822.
31. 　 Kaminskas E, Farrell A, Abraham S, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes [J]. Clin Cancer Res, 2005; 11(10)∶3604.

《中國普外基礎與臨床雜志》

組蛋白修飾與胃腸道惡性腫瘤的關系

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

組蛋白修飾與胃腸道惡性腫瘤的關系

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料